Therefore, because of the low application threshold, PSA monitoring is indispensable at the moment, and should be integrated into routine health examinations of men aged ≥45 years, as recommended in the latest 2018 German S3-guidelines for Prostate Cancer [116]. Here, KLK3 is linked to prostate carcinoma.